Akt Cross-links IL-4 Priming, Stem Cell Factor Signaling, and IgE-dependent Activation in Mature Human Mast Cells
Overview
Molecular Biology
Affiliations
Challenge of human mast cells with both stem cell factor (SCF) and IL-4 enhances antigen-dependent mediator release raising the assumption of intracellular crosstalk between the IL-4, SCF, and FcɛRI signaling pathways. Here, we analyzed the intracellular crosstalk of IL-4-, SCF-, and IgE-dependent activation pathways in mucosal mast cells isolated from human intestine. The release of β-hexosaminidase, leukotriene C(4), and IL-8, but not IL-6, was strongly enhanced in response to sequential challenge of mast cells with IL-4, SCF and FcɛRI cross-linking compared to stimulation by FcɛRI cross-linking alone. Previous studies revealed that MAPK and other serine/threonine kinases are involved in mast cell activation processes. Here we found that activation of mast cells by FcɛRI cross-linking alone results in phosphorylation of ERK and p38, but not of Akt. Stimulation with SCF alone also induced phosphorylation of ERK and p38, and additionally of Akt. IL-4 priming enhanced activation of ERK, but blocked activation of p38. Activation of p38 was required for IL-6 production explaining the inhibitory effect of IL-4 on IL-6 expression in human mast cells. Moreover, IL-4 priming that anteceded FcɛRI cross-linking induced activation of Akt. The combined challenge of mast cells with IL-4, SCF and FcɛRI cross-linking substantially up-regulated activation of Akt, whereas blocking of Akt inhibited the pronounced production and release of IL-8 in response to the three mast cell agonists. In summary, our data demonstrate that ERK, p38, and especially Akt play an important role in cross-linking IL-4 priming, SCF signaling, and IgE-dependent activation of mature human mast cells.
The Role of Stem Cell Factor, Epidermal Growth Factor and Angiopoietin-2 in HBV, HCV, HCC and NAFLD.
Radmanic L, Zidovec-Lepej S Life (Basel). 2022; 12(12).
PMID: 36556437 PMC: 9786337. DOI: 10.3390/life12122072.
Sowa A, Haas E, Hubener-Schmid J, Lorentz A Front Immunol. 2022; 13:870966.
PMID: 35558088 PMC: 9086395. DOI: 10.3389/fimmu.2022.870966.
Teegala L, Elshoweikh Y, Gudneppanavar R, Thodeti S, Pokhrel S, Southard E FASEB J. 2022; 36(5):e22273.
PMID: 35349200 PMC: 9298465. DOI: 10.1096/fj.202101838RRR.
Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.
He L, Yi W, Huang X, Long H, Lu Q Clin Rev Allergy Immunol. 2021; 61(3):424-448.
PMID: 34529248 DOI: 10.1007/s12016-021-08886-x.
Bilotta S, Paruchuru L, Feilhauer K, Koninger J, Lorentz A Int J Mol Sci. 2021; 22(14).
PMID: 34299258 PMC: 8307672. DOI: 10.3390/ijms22147640.